Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
Font Down Font Up

 
Hillenbrand Q3 Profit Down; Sees FY09 Results Near Low End Of Earlier View - Update
8/12/2009 9:47 AM  ET
TOP MARKET NEWS
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary
Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary
New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening
Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary
(RTTNews) -  Funeral service products dealer Hillenbrand, Inc. (HI: News ) reported Wednesday a decline in third-quarter profit, reflecting a 3.8% decrease in revenues on lower burial demand and a drop in investment income. The company also revealed that it now expects the results for the full year to linger at the lower end of its earlier guidance ranges.

For the third quarter, net income decreased to $25.4 million or $0.41 per share from $26.7 million or $0.42 per share in the previous year.

The results of the latest quarter included antitrust litigation costs of $0.2 million. The prior-year results included litigation costs of $0.6 million and separation costs of $0.1 million.

Excluding items, earnings decreased to $25.6 million from $27.4 million in the year-ago period.

On average, three analysts polled by Thomson Reuters expected the company to report earnings of $0.41 per share in the third quarter. Analysts' estimate typically exclude special items.

Net revenues for the period dipped 3.8% to $158.7 million from $165.0 million in the third quarter of the prior fiscal year. Analysts were expecting revenue of $155.90 million for the third quarter.

Kenneth Camp, Hillenbrand's chief executive, said, "Burial demand is typically diminished in the third and fourth quarters as a result of the seasonal effect of death trends. This year has been a bit unusual as there was a minimal instance of influenza and pneumonia, resulting in fewer North American burials,"
Camp added that the severity of the recession and uncertain economy apparently made consumers more cost-conscious while taking funeral purchase decisions.

Investment income dropped 56.8% to $1.9 million from $4.4 million, chiefly due to a $1.2 million decrease in the fair value of the investment portfolios of the limited partnerships held by the company.

Gross margin improved to 41.6% from 40.2%, helped by lower cost of diesel fuel and some raw materials. Operating expenses reduced 3.9% to $27.3 million from $28.4 million in the same quarter last year.

For the nine-month period, net income grew to $79.7 million or $1.29 per share from $74.0 million or $1.18 per share in fiscal 2008. Revenue came down to $496.0 million from $519.3 million in the same period last year.

Looking ahead, for fiscal 2009 the company now expects results to hover above the low end of the earlier outlook ranges. Previously Hillenbrand forecast net income to be between $97 million or $1.57 a share and $105 million or $1.70 a share on revenues ranging from $650 million to $670 million. The company had projected adjusted earnings to range from $101 million to $109 million, and $1.65 to $1.78 on a per share basis, for the full year.

To receive FREE breaking news email alerts for Hillenbrand Inc. and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
  Trading Center
 

More Breaking News-US

126  FDA Approves Bristol-Myers' Abilify To Treat Irritabilty In Pediatric Patients With Autistic Disorder - Update
125  EU Extends Review Deadline For Oracle's Proposed Takeover Of Sun Micro - Update
124  Pfizer's Geodon Approved As Adjunctive For Bipolar Disorder - Update
123  CF Nominees Enter Terra's Board - Update
122  Archipelago Learning Prices IPO Within Expected Range; Stock Soars - Update
121  Brown University And IBM Launch Multimillion-Dollar Supercomputer - Update
120  GLG Life Tech Starts Trading On Nasdaq; Shares Down 13.7% - Update
119  Global Defense Technology Prices IPO At $13/Share, Below Prior Estimate - Update
118  Dendreon Gets FDA Acceptance For Prostrate Cancer Drug Application - Update
117  Covidien's Pain Drug NDA Review Extended By FDA - Update
116  Inovio's Pre-clinincal Study Of Universal Flu Vaccines Reports Protective Response Against Multiple Influenza Strains; Stock Up - Update
115  Cloud Peak Energy Prices IPO At $15/shr - Update
114  Met-Pro Q3 Profit Plunges - Update
113  Boston Scientific Receives FDA's 510 (k)Clearance For WallFlex Fully Covered Esophageal Stent - Update
112  Pfizer Granted FDA Approval For Intravenous Formulation Of Revatio - Update
  

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS